Clinical trial ID No. (Registry) |
Intervention to
prevent infection |
Participant size |
Randomized |
Status |
Country (Pharma.) |
Antiviral |
Antiviral |
Antiviral |
Antiviral |
Antiviral |
Antiviral |
2020-000936-23 (EU-CTR)
|
Arm A: lopinavir/ritonavir
Arm B: interferon beta 1a
Arm C: remdesivir
|
3000
|
Yes
|
Recruiting
|
France
|
NCT04302766
(ClinicalTrials.gov)
|
Arm A: remdesivir
Arm B: standard treatment
|
Unspecified
|
Unspecified
|
Available
|
USA
|
NCT04292899
(ClinicalTrials.gov)
|
Arm A: remdesivir
Arm B: standard treatment
|
400
|
Yes
|
Recruiting
|
USA & Asia
|
NCT04292730
(ClinicalTrials.gov
|
Arm A: remdesivir
Arm B: standard treatment
|
600
|
Yes
|
Recruiting
|
USA & Asia
|
NCT04280705
(ClinicalTrials.gov)
|
Arm A: remdesivir
|
394
|
Yes
|
Recruiting
|
USA & South Koria
|
2020-000841-15
(EU-CTR)
|
Arm A: remdesivir
Arm B: standard treatment
|
400
|
Yes
|
Recruiting
|
Worldwide
|
2020-000842-32
(EU-CTR)
|
Arm A: remdesivir
Arm B: standard treatment
|
600
|
Yes
|
Recruiting
|
Worldwide
|
NCT04252664
(ClinicalTrials.gov)
|
Arm A: remdesivir
|
308
|
Yes
|
Recruiting
|
China
|
NCT04257656
(ClinicalTrials.gov)
|
Arm A: remdesivir
|
453
|
Yes
|
Recruiting
|
China
|
NCT04315948
(ClinicalTrials.gov)
|
Arm A: remdesivir
Arm B: standard treatment
|
3100
|
Yes
|
Recruiting
|
France
|
ChiCTR2000029600
(ICTPR)
|
Arm A: favipiravir and interferon alpha
atomisation
|
90
|
No
|
Recruiting
|
China
|
ChiCTR2000029544
(ICTPR)
|
Arm A: favipiravir
|
30
|
Yes
|
Not recruiting
|
China
|
ChiCTR2000029548
(ICTPR)
|
Arm A: favipiravir
|
30
|
Yes
|
Not recruiting
|
China
|
NCT04273763
(ClinicalTrials.gov)
|
Arm A: favipiravir and bromhexine (mucolytic),
umifenovir, interferon a2b
|
60
|
Yes
|
Recruiting
|
China (WanBangDe
Pharm. Group)
|
ChiCTR2000030113
(ICTPR)
|
Arm A: favipiravir
|
20
|
Yes
|
Recruiting
|
China
|
ChiCTR2000030254
(ICTPR)
|
Arm A: favipiravir
|
240
|
Yes
|
Recruiting
|
China
|
ChiCTR2000030987
(ICTPR)
|
Arm A: favipiravir and chloroquine
Arm B: favipiravir
|
150
|
Yes
|
Recruiting
|
China
|
NCT04310228
(ClinicalTrials.gov)
|
Arm A: favipiravir and tocilizumab
Arm B: favipiravir
|
150
|
Yes
|
Recruiting
|
China
|
JPRN-jRCTs041190120
(ICTPR)
|
Arm A: immediate favipiravir (Day 1–10)
Arm B: delayed favipiravir (Day 6–15)
|
86
|
Yes
|
Recruiting
|
Japan
|
ChiCTR2000029996
(ICTPR)
|
Arm A: low-dose favipiravir
Arm B: medium-dose favipiravir
Arm C: high-dose favipiravir
|
60
|
Yes
|
Recruiting
|
China
|
NCT04303299
(ClinicalTrials.gov)
|
Arm A: lopinavir/ritonavir and favipiravir
|
80
|
Yes
|
Not recruiting
|
Thailand
|
ChiCTR2000030922
(ICTPR)
|
Arm A: ribavirin and interferon alpha 2a
Arm B: umifenovir and ribavirin
|
30
|
Yes
|
Recruiting
|
China
|
NCT04276688
(ClinicalTrials.gov)
|
Arm A: ribavirin + lopinavir/ritonavir +
interferon beta 1b
|
70
|
Yes
|
Recruiting
|
Hong Kong
|
ChiCTR2000029387
(ICTPR)
|
Arm A: ribavirin and interferon alpha-1b
Arm B: ribavirin, lopinavir/ritonavir, and
interferon alpha-1b
|
108
|
Unspecified
|
Recruiting
|
China
|
ChiCTR2000029609
(ICTPR)
|
Arm A (mild–moderate): chloroquine
Arm B (mild–moderate):
lopinavir/ritonavir + chloroquine
Arm C (severe): chloroquine
|
205
|
No
|
Recruiting
|
China
|
NCT04303299
(ClinicalTrials.gov)
|
Arm A: oseltamivir and chloroquine
|
80
|
Yes
|
Not recruiting
|
Thailand
|
IRCT20100228003449N27
(ICTPR)
|
Arm A: hydroxychloroquine, lopinavir/
ritonavir, and interferon beta 1b
Arm B: hydroxychloroquine and
lopinavir/ritonavir
|
30
|
Yes
|
Recruiting
|
Iran
|
IRCT20100228003449N28
(ICTPR)
|
Arm A: hydroxychloroquine, lopinavir/
ritonavir, and interferon beta 1a
Arm B: hydroxychloroquine and
lopinavir/ritonavir
|
30
|
Yes
|
Recruiting
|
Iran
|
IRCT20100228003449N29
(ICTPR
|
Arm A: hydroxychloroquine, lopinavir/
ritonavir, and sofosbuvir/ledipasvir
Arm B: hydroxychloroquine and
lopinavir/ritonavir
|
50
|
Yes
|
Recruiting
|
Iran
|
JPRN-jRCTs031190227
(ICTPR)
|
Arm A: lopinavir/ritonavir and
hydroxychloroquine
|
50
|
Unspecified
|
Not recruiting
|
Japan
|
NCT04315948
(ClinicalTrials.gov)
|
Arm A: remdesivir
Arm B: lopinavir/ritonavir
Arm C: lopinavir/ritonavir and interferon
beta 1a
Arm D: hydroxychloroquine
Arm E: standard treatment
|
3100
|
Yes
|
Recruiting
|
France
|
NCT04273763
(ClinicalTrials.gov)
|
Arm A: bromhexine (mucolytic),
umifenovir, interferon a2b, and favipiravir
Arm B: umifenovir and interferon a2b
|
60
|
Yes
|
Recruiting
|
China
|
ChiCTR2000030254
(ICTPR)
|
Arm A: favipiravir
Arm B: umifenovir
|
240
|
Yes
|
Recruiting
|
China
|
ChiCTR2000030922
(ICTPR)
|
Arm A: interferon alpha 2a and ribavirin
Arm B: umifenovir and ribavirin
|
30
|
Yes
|
Recruiting
|
China
|
NCT04252885
(ClinicalTrials.gov)
|
Arm A: lopinavir/ritonavir + basic
treatment (unspecified)
Arm B: umifenovir + basic treatment
(unspecified)
|
125
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029573
(ICTPR)
|
Arm A: umifenovir
Arm B: Novaferon and umifenovir
Arm C: lopinavir/ritonavir
Arm D: umifenovir
Arm E: novaferon and
lopinavir/ritonavir
Arm F: novaferon and umifenovir
|
480
|
Yes
|
Not recruiting
|
China
|
ChiCTR2000029621
(ICTPR)
|
Arm A: umifenovir
Arm B: standard treatment
|
380
|
Yes
|
Recruiting
|
China
|
NCT04254874
(ClinicalTrials.gov)
|
Arm A: umifenovir
Arm B: umifenovir and pegylated
interferon alpha 2b
|
100
|
Yes
|
Recruiting
|
China
|
NCT04255017
(ClinicalTrials.gov)
|
Arm A: umifenovir
Arm B: oseltamivir
Arm C: lopinavir/ritonavir
|
400
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029993
(ICTPR)
|
Arm A: umifenovir and Liushen capsule
Arm B: standard treatment
|
40
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029592
(ICTPR)
|
Arm A: umifenovir
Arm B: without umifenovir
|
100
|
Unspecified
|
Not recruiting
|
China
|
NCT04261270
(ClinicalTrials.gov)
|
Arm A: ASC09 and oseltamivir
Arm B: ritonavir and oseltamivir
Arm C: oseltamivir
|
60
|
Yes
|
Recruiting
|
China
|
NCT04303299
(ClinicalTrials.gov)
|
Arm A: oseltamivir and chloroquine
Arm B: lopinavir/ritonavir and favipiravir
Arm C: lopinavir/ritonavir and oseltamivir
Arm D: lopinavir/ritonavir and oseltamivir
|
80
|
Yes
|
Not recruiting
|
Thailand
|
ChiCTR2000029609
(ICTPR)
|
Arm A (mild–moderate): lopinavir/ritonavir
Arm B (mild–moderate):
lopinavir/ritonavir + chloroquine
Arm C (severe): lopinavir/ritonavir
|
205
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029600
(ICTPR)
|
Arm A: interferon alpha atomisation
Arm B: lopinavir/ritonavir and interferon alpha
atomisation
|
90
|
No
|
Recruiting
|
China
|
NCT04261907
(ClinicalTrials.gov)
|
Arm A: ASC09/ritonavir
Arm B: lopinavir/ritonavir
|
160
|
Yes
|
Recruiting
|
China
(Ascletis Pharm)
|
ChiCTR2000029548
(ICTPR)
|
Arm A: baloxavir marboxil
Arm B: favipiravir
Arm C: lopinavir/ritonavir
|
30
|
Yes
|
Not recruiting
|
China
|
ChiCTR2000029541
(ICTPR)
|
Arm A: darunavir/cobicistat and
thymosin
Arm B: lopinavir/ritonavir and thymosin
Arm C: thymosin
|
100
|
Yes
|
Not recruiting
|
China
|
NCT04291729
(ClinicalTrials.gov)
|
Arm A: darunavir/ritonavir and
atomised interferon
Arm B: peginterferon a2
Arm C: interferon alpha (Novaferon)
Arm D: lopinavir/ritonavir
Arm E: atomised interferon + Chinese
medicine (unspecified)
|
50
|
Yes
|
Recruiting
|
China
(Ascletis Pharm)
|
ChiCTR2000030535
(ICTPR)
|
Arm A: ebastine and interferon alpha
inhalation and lopinavir
Arm B: interferon alpha inhalation and
lopinavir
|
100
|
Yes
|
Recruiting
|
China
|
2020-001113-21 (EU-CTR)
|
Arm A: lopinavir/ritonavir
Arm B: dexamethasone
Arm C: interferon beta 1a
Arm D: placebo
|
2000
|
Yes
|
Recruiting
|
UK
|
ChiCTR2000029468
(ICTPR)
|
Arm A: lopinavir/ritonavir and
emtricitabine/tenofovir
Arm B: lopinavir/ritonavir
|
120
|
Unspecified
|
Not recruiting
|
China
|
ChiCTR2000030166
(ICTPR)
|
Arm A: lopinavir/ritonavir and interferon
alpha 2b and Qing-Wen Bai-Du-Yin
granules
Arm B: lopinavir/ritonavir and interferon
alpha 2b
|
20
|
Yes
|
Not recruiting
|
China
|
ChiCTR2000030218
(ICTPR)
|
Arm A: lopinavir/ritonavir and
Xiyanping injection
Arm B: ritonavir
|
80
|
Unspecified
|
Recruiting
|
China
|
ChiCTR2000029539
(ICTPR)
|
Arm A: lopinavir/ritonavir
Arm B: standard treatment
|
328
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029496
(ICTPR)
|
Arm A: Novaferon atomisation inhalation
Arm B: lopinavir/ritonavir
Arm C: Novaferon and lopinavir/ritonavir
|
90
|
Yes
|
Recruiting
|
China
|
NCT04252274 (ClinicalTrials.gov)
|
Arm A: darunavir and cobicistat
Arm B: standard treatment
|
30
|
Yes
|
Recruiting
|
China
|
NCT04304053
(ClinicalTrials.gov)
|
Arm A: darunavir/cobicistat
Arm B: isolation
|
3040
|
Yes
|
Recruiting
|
Spain
|
Antimalarial |
Antimalarial |
Antimalarial |
Antimalarial |
Antimalarial |
Antimalarial |
ChiCTR2000030031
(ICTPR)
|
Arm A: chloroquine
|
120
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029988
(ICTPR)
|
Arm A: chloroquine
Arm B: standard treatment
|
80
|
Unspecified
|
Recruiting
|
China
|
ChiCTR2000029939
(ICTPR)
|
Arm A: chloroquine
Arm B: standard treatment
|
100
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029975
(ICTPR)
|
Arm A: chloroquine
|
10
|
No
|
Not recruiting
|
China
|
ChiCTR2000029837
(ICTPR)
|
Arm A: chloroquine
|
120
|
Yes
|
Not recruiting
|
China
|
ChiCTR2000029935
(ICTPR)
|
Arm A: chloroquine
|
100
|
No
|
Recruiting
|
China
|
ChiCTR2000029542
(ICTPR
|
Arm A: chloroquine
Arm B: standard treatment
|
20
|
Unspecified
|
Recruiting
|
China
|
ChiCTR2000030718
(ICTPR)
|
Arm A: chloroquine
Arm B: standard treatment
|
80
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029898
(ICTPR)
|
Arm A: hydroxychloroquine
Arm B: chloroquine
|
100
|
Yes
|
Recruiting
|
China
|
NCT04261517
(ClinicalTrials.gov)
|
Arm A: hydroxychloroquine
Arm B: standard of care
|
30
|
Yes
|
Recruiting
|
China
|
ChiCTR2000030054
(ICTPR
|
Arm A: hydroxychloroquine
Arm B: standard treatment
|
100
|
Yes
|
Not recruiting
|
China
|
ChiCTR2000029868
(ICTPR)
|
Arm A: hydroxychloroquine
Arm B: standard treatment
|
200
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029740
(ICTPR
|
Arm A: hydroxychloroquine
Arm B: standard treatment
|
78
|
Yes
|
Recruiting
|
China
|
ChiCTR2000029899
(ICTPR)
|
Arm A: hydroxychloroquine
Arm B: chloroquine
|
100
|
Yes
|
Recruiting
|
China
|
NCT04316377
(ClinicalTrials.gov)
|
Arm A: hydroxychloroquine
Arm B: standard treatment
|
202
|
Yes
|
Not recruiting
|
Norway
|
NCT04315896
(ClinicalTrials.gov)
|
Arm A: hydroxychloroquine
Arm B: placebo
|
500
|
Yes
|
Not recruiting
|
Mexico
|
ChiCTR2000029559
(ICTPR)
|
Arm A: hydroxychloroquine
Arm B: hydroxychloroquine
|
300
|
Unspecified
|
Recruiting
|
China
|
ChiCTR2000029803
(ICTPR)
|
Arm A: hydroxychloroquine (low dose)
Arm B: hydroxychloroquine (high dose)
|
320
|
Yes
|
Not recruiting
|
China
|
ChiCTR2000030082
(ICTPR)
|
Arm A: dihydroartemisinin/
piperaquine tablets combined with
antiviral treatment (presumed
alpha-interferon + umifenovir)
Arm B: alpha-interferon + umifenovir
|
40
|
Yes
|
Suspended
|
China
|
ChiCTR2000029803
(ICTPR)
|
Arm A: umifenovir (low dose)
Arm B: umifenovir (high dose)
|
320
|
Yes
|
Not recruiting
|
China
|